Wikipedia

Ecromeximab

Ecromeximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetGD3 ganglioside
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Molar mass145,255 g/mol
(verify)

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]

The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[3]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
  2. ^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
  3. ^ Adis insight: Ecromeximab
This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. The text was not checked or edited by anyone on our staff. Although the vast majority of Wikipedia® encyclopedia articles provide accurate and timely information, please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.